GC Pharma Preps For Life After Sale Of North American Subsidiaries
Convalescent Plasma Among Key Projects
South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.
You may also be interested in...
After the FDA's emergency use authorization for convalescent plasma, pushed on by President Trump, an alliance of firms is working with the NIH to conduct a robust study of a potentially more potent alternative.
Coronavirus Update: After Trump Pressure, US FDA Issues Emergency Use Authorization For Blood Plasma Therapy
US FDA Commissioner Stephen Hahn cites 35% improvement in study, but critics are dismayed by fudging of science and political pressure.
The South Korean pharma firm, which has been focusing on North America, decides to sell two subsidiaries there as the prolonged coronavirus pandemic further delays commercial manufacturing of plasma products.